Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675712 | 1.00 | SCN4A (0.45) | SCN4ADPP4F2GBA1CYP2C19 | |
| SCHEMBL11252039 | 0.83 | ANPEP (0.42) | — | |
| SCHEMBL9669874 | 0.78 | SCN4A (0.47) | SCN4ADPP4F2GBA1 | |
| SCHEMBL27966124 | 0.78 | DPP4 (0.41) | DPP4 | |
| SCHEMBL27966039 | 0.78 | ADRB2 (0.45) | SCN4ACYP2C19CYP2D6 | |
| SCHEMBL68782 | 0.78 | HTR2A (0.46) | DPP4F2CYP2C19GRIN1GRIN2A | |
| SCHEMBL266309 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL7406881 | 0.77 | CYP2C19 (0.57) | SCN4ADPP4F2CYP2C19GRIN2D | |
| SCHEMBL22705600 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2GBA1GRIN2D | |
| SCHEMBL898390 | 0.77 | CYP2C19 (0.57) | SCN4ADPP4F2CYP2C19GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549070-B | Preparation method of malavisuo and derivatives thereof | 中国科学院福建物质结构研究所 | 2022-12-06 | — | — | CN | disclosed |
| CN-113549070-A | Preparation method of malavisuo and derivatives thereof | 中国科学院福建物质结构研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080267906-A1 | Novel Spirotropane Compounds and Methods for the Modulation of Chemokine Receptor Activity | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | SCN4A 3153/4885DPP4 1852/4885F2 2495/4885 |
| US-20080267906-A1 | Novel Spirotropane Compounds and Methods for the Modulation of Chemokine Receptor Activity | CCR5, ACKR3, AVPR2 | SCN4A 1155/4885DPP4 2083/4885F2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.